- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) - - Median progression free survival of 5.8 months as of April 7th 2025 data cutoff - - Encouraging initial safety profile with no dose limiting toxicities at data cutoff - - Planning Phase 2 study initiation in 1H 2026 - - Conference call on Monday, May 12
Tech stocks have clawed back some recent losses, but uncertainty around tariffs is keeping investors cautious. Baird Tech Strategist Ted Mortonson joins Market Domination to break down the shift in sentiment, highlighting why some still see big names like Microsoft (MSFT) and Amazon (AMZN) as relatively safe bets. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
OK